Research ArticleCancer

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell–like phenotype

See allHide authors and affiliations

Science Translational Medicine  05 Aug 2020:
Vol. 12, Issue 555, eaax8313
DOI: 10.1126/scitranslmed.aax8313

Article Information

vol. 12 no. 555

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication April 26, 2019
  • Resubmitted December 19, 2019
  • Accepted for publication May 22, 2020
  • .

Author Information

  1. Barbara Lupo1,2,*,
  2. Francesco Sassi2,*,
  3. Marika Pinnelli1,2,
  4. Francesco Galimi1,2,
  5. Eugenia R. Zanella2,
  6. Valentina Vurchio1,2,
  7. Giorgia Migliardi1,2,
  8. Paolo Armando Gagliardi1,2,,
  9. Alberto Puliafito1,2,
  10. Daria Manganaro3,
  11. Paolo Luraghi2,,
  12. Michael Kragh4,§,
  13. Mikkel W. Pedersen4,
  14. Ivan D. Horak4,||,
  15. Carla Boccaccio1,2,
  16. Enzo Medico1,2,
  17. Luca Primo1,2,
  18. Daniel Nichol5,
  19. Inmaculada Spiteri5,
  20. Timon Heide5,
  21. Alexandra Vatsiou5,
  22. Trevor A. Graham6,
  23. Elena Élez7,
  24. Guillem Argiles7,
  25. Paolo Nuciforo7,
  26. Andrea Sottoriva5,
  27. Rodrigo Dienstmann7,
  28. Diego Pasini3,8,
  29. Elena Grassi2,
  30. Claudio Isella1,2,
  31. Andrea Bertotti1,2,,# and
  32. Livio Trusolino1,2,,,#
  1. 1Department of Oncology, University of Torino, 10060 Candiolo, Torino, Italy.
  2. 2Candiolo Cancer Institute—FPO IRCCS, 10060 Candiolo, Torino, Italy.
  3. 3European Institute of Oncology, 20139 Milano, Italy.
  4. 4Symphogen A/S, 2750 Ballerup, Denmark.
  5. 5The Institute of Cancer Research, London SW7 3RP, UK.
  6. 6Centre for Genomics and Computational Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
  7. 7Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
  8. 8Department of Health Sciences, University of Milano, 20142 Milano, Italy.
  1. #Corresponding author. Email: livio.trusolino{at}ircc.it (L.T.); andrea.bertotti{at}ircc.it (A.B.)
  • * These authors contributed equally to this work.

  • Present address: Institute of Cell Biology, University of Bern, 3012 Bern, Switzerland.

  • Present address: IFOM—The FIRC Institute of Molecular Oncology, 20139 Milano, Italy.

  • § Present address: Novo Nordisk A/S, 2880 Bagsvaerd, Denmark.

  • || Present address: Thessa Therapeutics, 038988 Singapore, Singapore.

  • These authors jointly supervised this work.

Altmetric

Article usage

Article usage: August 2020 to April 2021

AbstractFullPdf
Aug 20203350860349
Sep 202023111667
Oct 20202307851
Nov 20201856730
Dec 20201195944
Jan 20211164432
Feb 20211382021
Mar 20211503535
Apr 20211742223

Stay Connected to Science Translational Medicine